Combo Shows ' Impressive ' Survival Results in First-Line RCC Combo Shows ' Impressive ' Survival Results in First-Line RCC

The combination of lenvatinib and pembrolizumab outperformed sunitinib as first-line therapy for advanced clear-cell renal cell carcinoma (RCC) in the CLEAR trial.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news